Taipei, Taiwan

National Yang-Ming University is a research university located in Shipai, Beitou District, Taipei, Taiwan. It is famous for research in fields of Medicine, Life science and Biotechnology. In the 2010 QS Asian Universities Rankings, Yang Ming University was placed 4th among universities in Taiwan and 2nd in the field of Life Science & Biomedicine.Yang-Ming is named after the Chinese philosopher Wang Yangming. Wikipedia.


Time filter

Source Type

Patent
National Yang Ming University | Date: 2015-11-27

A dual targeting drug carrier is provided. The dual targeting drug carrier comprises a first targeting molecule and a second targeting molecule, wherein the targeting molecule comprises peptide, protein or antibody. The targeting molecule can bind to specific receptors, proteins, or glycoproteins to recognize the specific tumor cells, tissues, or organs. The dual targeting drug carriers are further conjugated with imaging agents, radioactive molecules (radiopharmaceuticals, isotopes, or chemotherapeutic drugs) or nanoparticles to form a conjugate


Patent
National Yang Ming University | Date: 2015-06-02

The present invention relates to a method for treating a subject with a cancer resistant to a chemotherapeutic drug comprising administering to said subject a therapeutically effective amount of prochlorperazine or its analog or metabolite, or a pharmaceutically acceptable salt thereof, in combination of the chemotherapeutic drug. The present invention also relates to a method for preventing cancer metastasis with the combination of prochlorperazine in combination of a chemotherapeutic drug.


Patent
National Yang Ming University | Date: 2016-07-26

A recombinant cytotoxin is provided. The recombinant cytotoxin of the present invention comprises a cytotoxin, a cell penetrating peptide (CPP), and Asp-Glu-Val-Asp (DEVD) sequence inserted in the cytotoxin. The recombinant cytotoxin can induce a targeting cell into the apoptotic pathway and be cleaved by the enzyme generated from apoptotic pathway. The present invention also provides a method for treating cancer, comprising administrating the recombinant cytotoxin to a subject.


Patent
National Yang Ming University | Date: 2016-07-06

A system of mapping a cardiac image of single heart chamber and a method thereof are disclosed. In the system and method thereof, one heart chamber (such as a left atrium, a left ventricular, a right atrium, right ventricular or aortic structure) can be selected in a 3D-based cardiac image (such as a CT or MRI image), and slices of the selected heart chamber are reconstructed and unwrapped by a 2D mapping visual display manner. The visual display and required angle alignment planes for subsequent analysis will be adjusted and achieved by operator manually, with specific global and regional architectural analysis performed by automatic algorithm.


Patent
National Yang Ming University and National Taiwan University | Date: 2016-02-04

The present invention relates to novel TMPK inhibitor and their methods of use. In particular, it relates to novel TMPK inhibitor of Formula (I) and therapeutics that decrease the cellular dTTP level to suppress the growth and inhibit DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.


Tyrosine family recombinases (YRs) are widely utilized in genome engineering systems because they can easily direct DNA rearrangement. Cre recombinases, one of the most commonly used types of YRs, catalyze site-specific recombination between two loxP sites without the need for high-energy cofactors, other accessory proteins or a specific DNA target sequence between the loxP sites. Previous structural, analytical ultracentrifuge and electrophoretic analyses have provided details of the reaction kinetics and mechanisms of Cre recombinase activity; whether there are reaction intermediates or side pathways involved has been left unaddressed. Using tethered particle motion (TPM), the Cre-mediated site-specific recombination process has been delineated, from beginning to end, at the single-molecule level, including the formation of abortive complexes and wayward complexes blocking inactive nucleoprotein complexes from entering the recombination process. Reversibility in the strand-cleavage/-ligation process and the formation of a thermally stable Holliday junction intermediate were observed within the Cre-mediated site-specific recombination process. Rate constants for each elementary step, which explain the overall reaction outcomes under various conditions, were determined. Taking the findings of this study together, they demonstrate the potential of single-molecule methodology as an alternative approach for exploring reaction mechanisms in detail. © 2012 The Author(s).


BACKGROUND: Substantial infective endocarditis (IE)-related morbidity and mortality may occur even after successful treatment. However, no previous study has explored long-term hard end points (ie, stroke, myocardial infarction, heart failure, cardiovascular death) in addition to all-cause mortality in IE survivors.METHODS AND RESULTS: A nationwide population-based cohort study was conducted among IE survivors identified with the use of the Taiwan National Health Insurance Research Database during 2000 to 2009. IE survivors were defined as those who survived after discharge from first hospitalization with a diagnosis of IE. A total of 10 116 IE survivors were identified. IE survivors were matched to control subjects without IE at a 1:1 ratio through the use of propensity scores. The primary outcomes were stroke, myocardial infarction, readmission for heart failure, and sudden cardiac death or ventricular arrhythmia. The secondary outcomes were repeat IE and all-cause mortality. Compared with the matched cohort, IE survivors had higher risks of ischemic stroke (adjusted hazard ratio [aHR], 1.59; 95% confidence interval [CI], 1.40-1.80), hemorrhagic stroke (aHR, 2.37; 95% CI, 1.90-2.96), myocardial infarction (aHR, 1.44; 95% CI, 1.17-1.79), readmission for heart failure (aHR, 2.24; 95% CI, 2.05-2.43), sudden death or ventricular arrhythmia (aHR, 1.69; 95% CI, 1.44-1.98), and all-cause death (aHR, 2.27; 95% CI, 2.14-2.40). Risk factors for repeat IE were older age, male sex, drug abuse, and valvular replacement after an initial episode of IE.CONCLUSION: Despite treatment, the risk of long-term major adverse cardiac events was substantially increased in IE survivors. © 2014 American Heart Association, Inc.


BACKGROUND—: Substantial infective endocarditis (IE)-related morbidity and mortality may occur even after successful treatment. However, no previous study has explored long-term hard endpoints (i.e., stroke, myocardial infarction, heart failure, cardiovascular death) in addition to all-cause mortality in IE survivors.METHODS AND RESULTS—: A nationwide population-based cohort study was conducted among IE survivors identified using Taiwanʼs National Health Insurance Research Database during 2000-2009. IE survivors were defined as those who survived after discharge from first hospitalization with a diagnosis of IE. A total of 10,116 IE survivors were identified. IE survivors were matched to control subjects without IE at a 1:1 ratio using propensity scores. The primary outcomes were stroke, myocardial infarction, readmission for heart failure, and sudden cardiac death or ventricular arrhythmia. The secondary outcomes were repeat IE and all-cause mortality. Compared with the matched cohort, IE survivors had higher risks of ischemic stroke (adjusted hazard ratio [aHR], 1.59; 95% confidence interval [CI], 1.40 to 1.80), hemorrhagic stroke (aHR, 2.37; 95% CI, 1.90 to 2.96), myocardial infarction (aHR, 1.44; 95% CI, 1.17 to 1.79), readmission for heart failure (aHR, 2.24; 95% CI, 2.05 to 2.43), sudden death or ventricular arrhythmia (aHR, 1.69; 95% CI, 1.44 to 1.98) and all-cause death (aHR, 2.27; 95% CI, 2.14 to 2.40). Risk factors for repeat IE were older age, male sex, drug abuser, and valvular replacement after an initial episode of IE.CONCLUSIONS—: Despite treatment, the risk of long-term major adverse cardiac events was substantially increased in IE survivors. © 2014 by the American College of Cardiology Foundation and the American Heart Association, Inc.


The present invention provides a method of obtaining a classification boundary, to limit an axial depth in a puncturing operation. The following steps of method comprises: At first, obtaining a plurality of tomographic images from the axial depth of a tissue is performed. Then, obtaining a plurality of characteristic values from the tomographic images, the characteristic values are classified by a Support Vector Machine method. A classification boundary will be obtained through a distribution of the graph for defining a specific compartment of the tissue. In addition, an automatic recognition method and system using the above mentioned method are also disclosed in the present invention.


Patent
National Yang Ming University | Date: 2016-01-13

The present invention provides a prism. The prism includes a lower surface, an upper surface, a first side surface and a second side surface. The first side surface and the second side surface are disposed between the upper surface and the lower surface. The first side surface and the second side surface of the prism are one-dimensional parabolic surfaces. The lower surface is used to receive light. The first side surface is used to reflect the light from the lower surface to the upper surface. The second side surface is used to reflect the light from the upper surface to the lower surface for further analysis in the process unit afterwards.

Loading National Yang Ming University collaborators
Loading National Yang Ming University collaborators